The 57.3% reduction in high-sensitivity C-reactive protein observed with oral semaglutide 50 mg would move patients from high cardiovascular risk (greater than 3 mg/dL) to intermediate risk (1-3 mg/dL), independent of glycemic changes
Deuschl G, Beghi E, Fazekas F, Varga T, Christoforidi KA, Sipido E, et al
doi: 10.4168/aair.2022.14.5.528
Unlike traditional dosing, which primarily targets appetite suppression and glucose regulation, microdosing semaglutide may provide a more gradual, sustained effect on the brain, immune system and overall cellular health, she notes
Additionally, since it is a stimulant, it can't be used long-term due to potential side effects and the risk of dependence
Therefore, for an individual with a history of chronic constipation, a highly personalized approach is vital